Secretome Therapeutics is a clinical-stage biotech company based in Plano, Texas that develops therapies derived from neonatal cardiac progenitor cells (nCPCs). Its lead product candidate, STM-01, is a cellular therapy intended to modulate inflammatory and fibrotic pathways and support myocardial function in Duchenne muscular dystrophy-associated cardiomyopathy, dilated cardiomyopathy, and heart failure with preserved ejection fraction. The company is also advancing STM-21, a secretome-based therapeutic currently in preclinical development, along with other nCPC-based programs. Secretome recently raised $30 million in a Series A financing from RA Capital Management to support operations and accelerate STM-01 toward pivotal Phase 2 and Phase 3 trials. The financing included a board change with David Lubner joining the Board and an RA Capital partner serving as a Board Observer. No revenue or user metrics were disclosed in the announcement.

Total raised

$52M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026